home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410e.zip
/
M94B0797.TXT
< prev
next >
Wrap
Text File
|
1994-11-11
|
3KB
|
42 lines
Document 0797
DOCN M94B0797
TI Treatment with zidovudine (AZT) is not associated with increased B cell
activation in HIV infection (Meeting abstract).
DT 9412
AU Widney D; Vander Meyden M; Martinez-Maza O; Dept. of Microbiology and
Immunology, UCLA Sch. of Medicine, Los; Angeles, CA 90024
SO Proc Annu Meet Am Assoc Cancer Res; 35:A1137 1994. Unique Identifier :
AIDSLINE ICDB/94602823
AB An increased frequency of AIDS-associated lymphoma has been reported to
be associated with AZT treatment. B cell hyperactivation, which is often
seen in HIV infection, is thought to contribute directly to the
development of lymphoma. To determine if AZT contributes directly to
lymphomagenesis by enhancing B cell activation, we determined whether in
vivo AZT treatment, or in vitro exposure, enhance B cell activation and
the production of interleukin-6 (IL-6), a B cell stimulatory cytokine.
Exposure to AZT in vitro did not appear to enhance spontaneous
immunoglobulin (Ig) or IL-6 secretion by B cells from HIV-infected
subjects or from HIV-uninfected control donors. Also, AZT exposure in
vitro did not enhance B cell activation induced by EBV or affect the
ability of T cells to regulate EBV-induced B cell activation. IgG, IgM
and IL-6 serum levels in HIV seropositive donors, did not increase
following the initiation of AZT treatment. Also, treatment with AZT was
not associated with B cell activation, as determined by the expression
of cell surface activation markers on circulating B cells by flow
cytometry. These results suggest that AZT does not induce or enhance B
cell activation in vivo or in vitro, and suggest that AZT does not
contribute to lymphomagenesis by enhancing B cell hyperstimulation.
Perhaps the elevated incidence of lymphomas seen in persons treated with
AZT is due to an increase in life-span associated with antiretroviral
treatment, which places them at risk for developing lymphoma for a
greater period of time.
DE B-Lymphocytes/*DRUG EFFECTS/IMMUNOLOGY HIV Infections/*DRUG
THERAPY/IMMUNOLOGY Human Interleukin-6/BIOSYNTHESIS Lymphocyte
Transformation/*DRUG EFFECTS/IMMUNOLOGY Lymphoma,
AIDS-Related/*CHEMICALLY INDUCED/IMMUNOLOGY Risk Factors
Zidovudine/ADVERSE EFFECTS/*THERAPEUTIC USE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).